Commentary

Video

Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLC

Author(s):

Benjamin Besse, MD,Gregory J. Riely, MD, PhD

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Related Content
Cancer | Image Credit: © catalin - stock.adobe.com
January 23rd 2025

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

TKIs in Second-Line HER2-Mutant NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12